Neptune Technologies (NEPT) suffered a major setback in a tragic explosion to its main production facility in Quebec on Nov. 8. Since then and up until today, trading in the company's shares had been frozen. Markets reacted by sending shares down 24%, reflecting the major production setback from the destroyed facility. The loss will impact the company's main product, a krill-oil-based nutritional supplement. However, one of its subsidiaries has aspirations to compete with fish-oil based pharmaceuticals from companies such as Amarin (AMRN) and GlaxoSmithKline (GSK 1.56%)
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
This Oil Maker Gets Krilled
NASDAQ: NEPT
Neptune Wellness Solutions

Neptune shares fall sharply on its first day trading since a plant explosion.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.